TYRA - Tyra Biosciences, Inc.
IEX Last Trade
14.08
-0.040 -0.284%
Share volume: 2,533
Last Updated: Fri 27 Dec 2024 08:30:17 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$14.12
-0.04
-0.28%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.16%
1 Month
-8.13%
3 Months
-37.02%
6 Months
-4.85%
1 Year
5.00%
2 Year
71.53%
Key data
Stock price
$14.08
DAY RANGE
$14.11 - $14.58
52 WEEK RANGE
$12.06 - $29.60
52 WEEK CHANGE
$6.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Todd J. Harris
Region: US
Website: tyra.bio
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: tyra.bio
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
Recent news